Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis.
Clin Microbiol Infect
; 28(9): 1203-1210, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: covidwho-1850887
ABSTRACT
BACKGROUND:
The benefits of remdesivir in the treatment of hospitalized patients with COVID-19 remain debated with the National Institutes of Health and the World Health Organization providing contradictory recommendations for and against use.OBJECTIVES:
To evaluate the role of remdesivir for hospitalized inpatients as a function of oxygen requirements. DATA SOURCES Beginning with our prior systematic review, we searched MEDLINE using PubMed from 15 January 2021 through 5 May 2022. STUDY ELIGIBILITY CRITERIA Randomised controlled trials; all languages.PARTICIPANTS:
All hospitalized adults with COVID-19.INTERVENTIONS:
Remdesivir, in comparison to either placebo, or standard of care. ASSESSMENT OF RISK OF BIAS We used the ROB-2 criteria. METHODS OF DATASYNTHESIS:
The primary outcome was mortality, stratified by oxygen use (none, supplemental oxygen without mechanical ventilation, and mechanical ventilation). We conducted a frequentist random effects meta-analysis on the risk ratio scale and, to contextualize the probabilistic benefits, we also performed a Bayesian random effects meta-analysis on the risk difference scale. A ≥1% absolute risk reduction was considered clinically important.RESULTS:
We identified eight randomized trials, totaling 10 751 participants. The risk ratio for mortality comparing remdesivir vs. control was 0.77 (95% CI, 0.5-1.19) in the patients who did not require supplemental oxygen; 0.89 (95% CI, 0.79-0.99) for nonventilated patients requiring oxygen; and 1.08 (95% CI, 0.88-1.31) in the setting of mechanical ventilation. Using neutral priors, the probabilities that remdesivir reduces mortality were 76.8%, 93.8%, and 14.7%, respectively. The probability that remdesivir reduced mortality by ≥ 1% was 77.4% for nonventilated patients requiring oxygen.CONCLUSIONS:
Based on this meta-analysis, there is a high probability that remdesivir reduces mortality for nonventilated patients with COVID-19 requiring supplemental oxygen therapy. Treatment guidelines should be re-evaluated.Palavras-chave
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Assunto principal:
Tratamento Farmacológico da COVID-19
Tipo de estudo:
Estudo experimental
/
Estudo prognóstico
/
Ensaios controlados aleatorizados
/
Revisões
/
Revisão sistemática/Meta-análise
Limite:
Adulto
/
Humanos
País/Região como assunto:
América do Norte
Idioma:
Inglês
Revista:
Clin Microbiol Infect
Assunto da revista:
Doenças Transmissíveis
/
Microbiologia
Ano de publicação:
2022
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS